SUPPLEMENTAL MATERIALS

Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium

Naomi R Wray* 1, 2 Stephan Ripke* 3, 4, 5 Manuel Mattheisen* 6, 7, 8 Maciej Trzaskowski 1 Enda M Byrne 1 Abdel Abdellaoui 9 Mark J Adams 10 Esben Agerbo 11, 12, 13 Tracy M Air 14 Till F M Andlauer 15, 16 Silviu-Alin Bacanu 17 Marie Bækvad-Hansen 13, 18 Aartjan T F Beekman 19 Tim B Bigdeli 17, 20 Elisabeth B Binder 15, 21 Julien Bryois 22 Henriette N Buttenschøn 13, 23, 24 Jonas Bybjerg-Grauholm 13, 18 Na Cai 25, 26 Enrique Castelao 27 Jane Hvarregaard Christensen 8, 13,24 Toni-Kim Clarke 10 Jonathan R I Coleman 28 Lucía Colodro-Conde 29 Baptiste Couvy-Duchesne 2, 30 Nick Craddock 31 Gregory E Crawford 32, 33 Gail Davies 34 Ian J Dearv 34 Franziska Degenhardt 35 Eske M Derks 29 Nese Direk 36, 37 Conor V Dolan 9 Erin C Dunn 38, 39, 40 Thalia C Eley 28 Valentina Escott-Price 41 Farnush Farhadi Hassan Kiadeh 42 Hilary K Finucane 43, 44 Jerome C Foo 45 Andreas J Forstner 35, 46, 47, 48 Josef Frank 45 Héléna A Gaspar 28 Michael Gill 49 Fernando S Goes 50 Scott D Gordon 29 Jakob Grove 8, 13, 24, 51 Lynsey S Hall 10, 52

Christine Søholm Hansen 13, 18 Thomas F Hansen 53, 54, 55 Stefan Herms 35, 47 Ian B Hickie 56 Per Hoffmann 35, 47 Georg Homuth 57 Carsten Horn 58 Jouke-Jan Hottenga 9 David M Hougaard 13,18 David M Howard 10, 28 Marcus Ising 59 Rick Jansen 19 Ian Jones 60 Lisa A Jones 61 Eric Jorgenson 62 James A Knowles 63 Isaac S Kohane 64, 65, 66 Julia Kraft 4 Warren W. Kretzschmar 67 Zoltán Kutalik 68, 69 Yihan Li 67 Penelope A Lind 29 Donald J MacIntyre 70, 71 Dean F MacKinnon 50 Robert M Maier 2 Wolfgang Maier 72 Jonathan Marchini 73 Hamdi Mbarek 9 Patrick McGrath 74 Peter McGuffin 28 Sarah E Medland 29 Divya Mehta 2, 75 Christel M Middeldorp 9, 76, 77 **Evelin Mihailov 78** Yuri Milaneschi 19 Lili Milani 78 Francis M Mondimore 50 Grant W Montgomery 1 Sara Mostafavi 79, 80 Niamh Mullins 28 Matthias Nauck 81, 82 Bernard Ng 80 Michel G Nivard 9 Dale R Nyholt 83 Paul F O'Reilly 28 Hogni Oskarsson 84 Michael J Owen 60 Jodie N Painter 29 Carsten Bøcker Pedersen 11, 12, 13

Marianne Giørtz Pedersen 11, 12, 13 Roseann E Peterson 17, 85 Erik Pettersson 22 Wouter J Peyrot 19 Giorgio Pistis 27 Danielle Posthuma 86, 87 Jorge A Quiroz 88 Per Qvist 8, 13, 24 John P Rice 89 Brien P. Riley 17 Margarita Rivera 28, 90 Saira Saeed Mirza 36 Robert Schoevers 91 Eva C Schulte 92, 93 Ling Shen 62 Jianxin Shi 94 Stanley I Shyn 95 Engilbert Sigurdsson 96 Grant C B Sinnamon 97 Johannes H Smit 19 Daniel J Smith 98 Hreinn Stefansson 99 Stacy Steinberg 99 Fabian Streit 45 Jana Strohmaier 45 Katherine E Tansey 100 Henning Teismann 101 Alexander Teumer 102 Wesley Thompson 13, 54, 103, 104 Pippa A Thomson 105 Thorgeir E Thorgeirsson 99 Matthew Traylor 106 Jens Treutlein 45 Vassily Trubetskoy 4 Andrés G Uitterlinden 107 Daniel Umbricht 108 Sandra Van der Auwera 109 Albert M van Hemert 110 Alexander Viktorin 22 Peter M Visscher 1, 2 Yunpeng Wang 13, 54, 104 Bradley T. Webb 111 Shantel Marie Weinsheimer 13, 54 Jürgen Wellmann 101 Gonneke Willemsen 9 Stephanie H Witt 45 Yang Wu 1 Hualin S Xi 112

Jian Yang 2, 113	Qingqin S Li 129	James B Potash 137
Futao Zhang 1	Susanne Lucae 59	Martin Preisig 27
Volker Arolt 114	Pamela AF Madden 89	Marcella Rietschel 45
Bernhard T Baune 115, 116, 117	Patrik K Magnusson 22	Catherine Schaefer 62
Klaus Berger 101	Nicholas G Martin 29	Thomas G Schulze 45, 93, 138,
Dorret I Boomsma 9	Andrew M McIntosh 10, 34	139, 140
Sven Cichon 35, 47, 118, 119	Andres Metspalu 78, 130	Jordan W Smoller 38, 39, 40
Udo Dannlowski 114	Ole Mors 13, 131	Kari Stefansson 99, 141
EJC de Geus 9, 120	Preben Bo Mortensen 11, 12,	Henning Tiemeier 36, 142, 143
J Raymond DePaulo 50	13, 24	Rudolf Uher 144
Enrico Domenici 121	Bertram Müller-Myhsok 15,	Henry Völzke 102
Katharina Domschke 122, 123	132, 133	Myrna M Weissman 74, 145
Tõnu Esko 5, 78	Merete Nordentoft 13, 134	Thomas Werge 13, 54, 146
Hans J Grabe 109	Markus M Nöthen 35	Cathryn M Lewis* 28, 147
Steven P Hamilton 124	Michael C O'Donovan 60	Douglas F Levinson* 148
Caroline Hayward 125	Sara A Paciga 135	Gerome Breen* 28, 149
Andrew C Heath 89	Nancy L Pedersen 22	Anders D Børglum* 8, 13, 24
Kenneth S Kendler 17	Brenda WJH Penninx 19	Patrick F Sullivan* 22, 150,
Stefan Kloiber 59, 126, 127	Roy H Perlis 38, 136	151,
Glyn Lewis 128	David J Porteous 105	

1, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, AU

2, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, AU

3, Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, US

4, Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, DE

5, Medical and Population Genetics, Broad Institute, Cambridge, MA, US

6, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wurzburg, Wurzburg, DE

7, Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SE

8, Department of Biomedicine, Aarhus University, Aarhus, DK

9, Dept of Biological Psychology & EMGO+ Institute for Health and Care Research, Vrije Universiteit Amsterdam, Amsterdam, NL

10, Division of Psychiatry, University of Edinburgh, Edinburgh, GB

11, Centre for Integrated Register-based Research, Aarhus University, Aarhus, DK

12, National Centre for Register-Based Research, Aarhus University, Aarhus, DK

13, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research,, DK

14, Discipline of Psychiatry, University of Adelaide, Adelaide, SA, AU

15, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, DE

16, Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, DE

17, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, US

18, Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, DK

19, Department of Psychiatry, Vrije Universiteit Medical Center and GGZ inGeest, Amsterdam, NL

20, Virginia Institute for Psychiatric and Behavior Genetics, Richmond, VA, US

21, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, US

22, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE

23, Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, DK

24, iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, DK

25, Human Genetics, Wellcome Trust Sanger Institute, Cambridge, GB

26, Statistical genomics and systems genetics, European Bioinformatics Institute (EMBL-EBI), Cambridge, GB

27, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH

28, Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB

29, Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AU

30, Centre for Advanced Imaging, The University of Queensland, Brisbane, QLD, AU

31, Psychological Medicine, Cardiff University, Cardiff, GB

32, Center for Genomic and Computational Biology, Duke University, Durham, NC, US

33, Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, US

34, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, GB

35, Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, DE

36, Epidemiology, Erasmus MC, Rotterdam, Zuid-Holland, NL

37, Psychiatry, Dokuz Eylul University School Of Medicine, Izmir, TR

38, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, US

39, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, US

40, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, US

41, Neuroscience and Mental Health, Cardiff University, Cardiff, GB

42, Bioinformatics, University of British Columbia, Vancouver, BC, CA

43, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, US

44, Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA, US

45, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty

Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, DE

46, Department of Psychiatry (UPK), University of Basel, Basel, CH

47, Department of Biomedicine, University of Basel, Basel, CH

48, Centre for Human Genetics, University of Marburg, Marburg, DE

49, Department of Psychiatry, Trinity College Dublin, Dublin, IE

50, Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, US

51, Bioinformatics Research Centre, Aarhus University, Aarhus, DK

52, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, GB

53, Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, DK

54, Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, DK

55, iPSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, Copenhagen, DK

56, Brain and Mind Centre, University of Sydney, Sydney, NSW, AU

57, Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University

Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Mecklenburg-Vorpommern, DE

58, Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH

59, Max Planck Institute of Psychiatry, Munich, DE

60, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, GB

61, Department of Psychological Medicine, University of Worcester, Worcester, GB

62, Division of Research, Kaiser Permanente Northern California, Oakland, CA, US

63, Psychiatry & The Behavioral Sciences, University of Southern California, Los Angeles, CA, US

64, Department of Biomedical Informatics, Harvard Medical School, Boston, MA, US

65, Department of Medicine, Brigham and Women's Hospital, Boston, MA, US

66, Informatics Program, Boston Children's Hospital, Boston, MA, US

67, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, GB

68, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne, VD, CH

69, Swiss Institute of Bioinformatics, Lausanne, VD, CH

70, Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, GB

71, Mental Health, NHS 24, Glasgow, GB

72, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE

73, Statistics, University of Oxford, Oxford, GB

74, Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, US

75, School of Psychology and Counseling, Queensland University of Technology, Brisbane, QLD, AU

76, Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, South Brisbane, QLD, AU

77, Child Health Research Centre, University of Queensland, Brisbane, QLD, AU

78, Estonian Genome Center, University of Tartu, Tartu, EE

79, Medical Genetics, University of British Columbia, Vancouver, BC, CA

80, Statistics, University of British Columbia, Vancouver, BC, CA

81, DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE

82, Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE

83, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, AU

84, Humus, Reykjavik, IS

85, Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US

86, Clinical Genetics, Vrije Universiteit Medical Center, Amsterdam, NL

87, Complex Trait Genetics, Vrije Universiteit Amsterdam, Amsterdam, NL

- 88, Solid Biosciences, Boston, MA, US
- 89, Department of Psychiatry, Washington University in Saint Louis School of Medicine, Saint Louis, MO, US

90, Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, ES

91, Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, NL

92, Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University Munich, Munich, DE

93, Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig Maximilian University Munich, Munich, DE

94, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, US

95, Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, US

- 96, Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik, IS
- 97, School of Medicine and Dentistry, James Cook University, Townsville, QLD, AU
- 98, Institute of Health and Wellbeing, University of Glasgow, Glasgow, GB

99, deCODE Genetics / Amgen, Reykjavik, IS

100, College of Biomedical and Life Sciences, Cardiff University, Cardiff, GB

101, Institute of Epidemiology and Social Medicine, University of Münster, Münster, Nordrhein-Westfalen, DE

102, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE

103, Department of Psychiatry, University of California, San Diego, San Diego, CA, US

104, KG Jebsen Centre for Psychosis Research, Norway Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NO

105, Medical Genetics Section, CGEM, IGMM, University of Edinburgh, Edinburgh, GB

106, Clinical Neurosciences, University of Cambridge, Cambridge, GB

107, Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, NL

108, Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases

Discovery & Translational Medicine Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH 109, Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, DE

110, Department of Psychiatry, Leiden University Medical Center, Leiden, NL

111, Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US

112, Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Cambridge, MA, US

113, Institute for Molecular Bioscience; Queensland Brain Institute, The University of Queensland, Brisbane, QLD, AU

114, Department of Psychiatry, University of Münster, Münster, Nordrhein-Westfalen, DE

115, Department of Psychiatry, University of Münster, Münster, DE

116, Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, AU

117, Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, AU

118, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, CH

119, Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, DE

120, Amsterdam Public Health Institute, Vrije Universiteit Medical Center, Amsterdam, NL

121, Centre for Integrative Biology, Università degli Studi di Trento, Trento, Trentino-Alto Adige, IT

122, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, DE

123, Center for NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, DE

124, Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, US

125, Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, GB

126, Department of Psychiatry, University of Toronto, Toronto, ON, CA

127, Centre for Addiction and Mental Health, Toronto, ON, CA

- 128, Division of Psychiatry, University College London, London, GB
- 129, Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, US
- 130, Institute of Molecular and Cell Biology, University of Tartu, Tartu, EE
- 131, Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, DK
- 132, Munich Cluster for Systems Neurology (SyNergy), Munich, DE
- 133, University of Liverpool, Liverpool, GB
- 134, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, DK
- 135, Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, US
- 136, Psychiatry, Harvard Medical School, Boston, MA, US
- 137, Psychiatry, University of Iowa, Iowa City, IA, US
- 138, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, US
- 139, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, Niedersachsen, DE
- 140, Human Genetics Branch, NIMH Division of Intramural Research Programs, Bethesda, MD, US
- 141, Faculty of Medicine, University of Iceland, Reykjavik, IS
- 142, Child and Adolescent Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 143, Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, NL
- 144, Psychiatry, Dalhousie University, Halifax, NS, CA
- 145, Division of Epidemiology, New York State Psychiatric Institute, New York, NY, US
- 146, Department of Clinical Medicine, University of Copenhagen, Copenhagen, DK
- 147, Department of Medical & Molecular Genetics, King's College London, London, GB
- 148, Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, US
- 149, NIHR Maudsley Biomedical Research Centre, King's College London, London, GB
- 150, Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, US
- 151, Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, US

Cohort description

Data came from the Avon Longitudinal Study of Parents and Children (ALSPAC), a prospective, longitudinal birth cohort of children born to mothers who were living in the county of Avon England (120 miles west of London) with estimated delivery dates between April 1991 and

December 1992 ALSPAC was designed to identify the determinants of health across the

lifespan, with an emphasis on genetic and environmental factors. The initial number of

pregnancies enrolled is 14,541 (for these at least one questionnaire has been returned or a

"Children in Focus" clinic had been attended by 19/07/99). Of these initial pregnancies, there

was a total of 14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive

at 1 year of age. When the oldest children were approximately 7 years old, an attempt was made

to bolster the initial sample with eligible cases who had failed to join the study originally,

resulting in an additional 913 children being enrolled. As such, the total sample size for analyses

using any data collected after the age of seven is therefore 15,454 pregnancies, resulting in 15,589 fetuses. Of these 14,901 were alive at 1 year of age. The ALSPAC website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: www.bristol.ac.uk/alspac/researchers/our-data/. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committee. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

Genotyping, quality control, and imputation

We performed standard quality control measures to exclude youths on the basis of gender mismatch, minimal or excessive heterozygosity, individual genotyping call rates < 97%, insufficient sample replication (IBD<0.8), cryptic relatedness (IBD>0.1), and non-European ancestry (assessed using multidimensional scaling analysis and compared to HapMap II, release 22). For the current analyses, we further excluded 21 youths who self-reported as non-whites. We excluded genotyped SNPs based on the following criteria: minor allele frequency <1%; missing rate >5%; and significant deviation from Hardy-Weinberg Equilibrium (p<1e-7). We conducted imputation using Impute V2.2.2 against the 1000 genomes reference panel (Phase 1, version 3), with 2,186 reference haplotypes including non-Europeans (Abecasis et al., 2012; Marchini, Howie, Myers, McVean, & Donnelly, 2007).

Polygenic risk score (PRS) generation and selection

Prior to score construction, we performed additional genomic quality control procedures by removing imputed SNPs with imputation quality metric score <0.8, MAF <1%, call rate <95%, and HWE p<1e-6. SNPs were then pruned for linkage disequilibrium using p-value informed clump-based pruning in PLINK v1.90 (r²=0.25 within a 250kb window). We created the PRS in PLINK v.1.07, using methods described by Purcell et al., where the PRS for each youth was the sum of the risk alleles (0, 1, or 2) for each SNP at a given p-value threshold weighted by the logarithm of its odds ratio (OR) for MDD in the PGC GWAS (Purcell et al., 2007). Using PGC-MDD2 as the discovery sample and the ALSPAC cohort as the training sample, we selected independent subsets of SNPs from GWAS summary data at 10 GWAS significance thresholds (p_T), 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1. We standardized all PRS prior to analysis so that all reported ORs could be interpreted as a one standard deviation increase in the score. As the PRS with $p_T < 0.4$ explained the most phenotypic variance in the analytic sample compared to the other scores (Wald omnibus value = 26.9; Chi-squared p-value = 1e-4; Figure S5), we focused on the results from this 'best model fit' score. For comparison, we include sensitivity analyses using the other p-value thresholds in Figure S6.

Author contributions

AAL analyzed the data, compiled the results, and wrote the manuscript. MH performed the analyses in MPlus. MW generated the polygenic risk scores. KC and JC helped with writing and interpretation of findings. YZ helped with data analysis of the ALSPAC cohort. ECD helped write the manuscript and compile the results. All authors provided critical feedback at all stages of the manuscript.

Supplemental references

- Abecasis, G. R., Auton, A., Brooks, L. D., DePristo, M. A., Durbin, R. M., Handsaker, R. E., Kang, H. M., et al. (2012). An integrated map of genetic variation from 1,092 human genomes. *Nature*, 491(7422), 56–65.
- Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007). A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet*, 39(7), 906–913. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17572673
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*, 81(3), 559–575. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17701901

SUPPLEMENTAL TABLES

Table S1. Summary of the analytical subsample from the ALSPAC cohortOriginal SampleAnalytic SampleOriginal vs.

	Original Sample	Analytic Sample	Original vs
	(N=15445)	(N=7,308)	Analytic
	n (%)	n (%)	χ2 p-value
Sex			
Males	7542 (51.3)	3707 (50.7)	0.151
Females	7152 (48.7)	3601 (49.3)	
Race			
Non-white	611 (5.1)	0 (0)	< 0.001
White	11488 (94.9)	6639 (100.0)	
Age of Mother at Child's Birth			
Ages 15-19	650 (4.6)	142 (2.0)	< 0.001
Ages 20-35	12363 (88.4)	6281 (89.8)	
Age 36+	968 (6.9)	575 (8.2)	
Parental Social Class			
Professional	1419 (9.6)	942 (12.9)	<0.001
Managerial and technical	4288 (29.0)	2583 (35.3)	
Skilled, non-manual	2623 (17.8)	1456 (19.9)	
Skilled, manual	909 (6.2)	438 (6.0)	
Semi-skilled, manual	270 (1.8)	125 (1.7)	
Unskilled, manual/other	5254 (35.6)	1764 (24.1)	

Number of previous pregnancies

0	5800 (44.7)	3045 (44.9)	< 0.001
1	4550 (35.0)	2480 (36.6)	
2	1860 (14.3)	921 (13.6)	
3+	772 (5.9)	330 (4.9)	
Birth weight (g)			
< 3000	3649 (24.8)	1572 (21.5)	< 0.001
3000 - 3499	4924 (33.5)	2446 (33.5)	
3500 - 3999	4382 (29.8)	2338 (32.0)	
>= 4000	1735 (11.8)	952 (13.0)	
Maternal Education			
less than O-level	3735 (30.0)	1575 (23.3)	< 0.001
O-level	4303 (34.6)	2366 (35.1)	
A-level	2795 (22.5)	1724 (25.5)	
Degree or Above	1603 (12.9)	1084 (16.1)	
Maternal Marital Status			
Never Married	2522 (19.2)	950 (13.9)	< 0.001
Widowed/Divorced/Separated	787 (6.0)	364 (5.3)	
Married	9838 (74.8)	5529 (80.8)	

Gene	Chr	Start	Stop	# of SNPs	R ²	P-value	Association
ZFAND1	8	82613566	82633539	70	0.0054	9.74e ⁻⁵	HR vs MS
SIX5	19	46268043	46272497	3	0.0029	9.07e ⁻⁶	AUC
DMPK	19	46272975	46285815	17	0.0030	5.52e ⁻⁵	AUC
DKK1	10	54074041	54077417	5	0.0023	8.56e ⁻⁵	AUC
SIX5	19	46268043	46272497	3	0.0030	6.14e ⁻⁶	Intercept
DMPK	19	46272975	46285815	17	0.0035	1.10e ⁻⁵	Intercept
SMDT1	22	42475695	42480288	6	0.0030	1.52e ⁻⁵	Intercept

 Table S2. Summary of gene-based hits using MAGMA.

*HR = high/renitent class; MS = minimal symptoms class; AUC = cumulative burden of depressive symptoms; intercept = onset of depressive symptoms

SUPPLEMENTAL FIGURES




Figure S1. Flowchart of ALSPAC sample selection. Of the eligible participants after 1 year (14,901), two subsamples were selected: those with genetic data (9,912) and those with at least one measure of depressive symptoms from age 4-16 (11,641). Following quality control measures, the genetic subsample was reduced to 8,082 individuals. The overlap between these two samples was 7,308 individuals, which we defined as the analytical sample for the polygenic risk score (PRS) analyses of depressive symptom trajectories, as well as gene-level associations with persistence and onset of symptoms using MAGMA. The analytical sample was further subset to 5,922 individuals for the trajectory class-based MAGMA analysis, which focused solely on youths classified as high/stable or minimal symptoms for the depressive symptom trajectories.




Figure S2. Polygenic risk scores identified differences in membership to classes of depressive symptom trajectories. Odds ratios were calculated to determine the odds of membership of each class versus the referent given a one unit increase in polygenic risk score (PRS). While four contrasts were significant (p<0.05), only three remained significant after multiple test correction (high/stable vs minimal symptoms; high/stable vs childhood decrease; high/unstable vs minimal symptoms).




Figure S3. Quantile-quantile (QQ) plots of gene-level genome-wide associations show good model fit of the MAGMA analysis. A) The QQ plot of the high/stable (HS) and minimal symptoms (MS) classes of depressive symptoms trajectories showed good model fit, with a slight downward skew. **B)** The QQ plot of depressive symptom persistence across age 4-16, defined as the area under the curve (AUC) of the trajectory was slightly skewed upward, but showed good model fit. **C)** The QQ plot of depressive symptom onset, defined by the intercept of the trajectory, was also slightly skewed upward and showed good model fit.




Figure S4. Depressive symptom developmental features showed nominal gene-level associations. A) The contrast of high/renitent (HR) and minimal symptoms (MS) classes showed no significant associations. **B)** Depressive symptom persistence (AUC) showed only suggestive associations. **C)** Depressive symptom onset (intercept) showed only suggestive associations as well. The significance threshold was set at 2.93e-6 (red) and the suggestive threshold was set at 1e-4 (blue).




Figure S5. The PRS with pT<0.4 was the 'best fit' polygenic risk score. Using the Wald omnibus test of parameter constraints, we show that the polygenic risk score (PRS) generated with the p-value threshold of p<0.4 (green) explained the most variance in the depression trajectories.




Figure S6. Similar odds ratios for significant contrasts were detected across different PRS thresholds. A sensitivity analysis of the PRS generated using different p-value thresholds

revealed similar trends as that identified with the 'best fit' PRS (p <0.4; shown in green).